In line with the trend, Sydney-based contract research organisation (CRO), Novotech has conducted a statistical analysis which indicates that, between 2017 and 2021, over 70,000 new clinical trials were registered in the APAC region, the US, and the EU5 (France, Germany, Italy, Spain, UK). During the forecast period, the APAC region reportedly accounted for 50 per cent of the trials, followed by the US (29 per cent) and the EU5 (17 per cent). China recorded the largest number of new trials, followed by the US and India. Dr John Moller, CEO Novotech, provides his views on the APAC CRO market.
What is your outlook for the Asia Pacific CRO market in 2023?
The latest Novotech research with GlobalData shows that APAC continues to be a global hub for clinical trials. Our current data shows it had the highest growth rate globally with 9 per cent CAGR in 2022. In addition, the APAC is well positioned with 7,600 clinical sites, more than any other region, combined with higher urban density which translates to expedited patient access. We expect the APAC to continue this exceptional growth through 2023 and beyond, fueled by access to patient populations, quality medical and site facilities, site capacity and the ability to deliver accelerated timelines with globally accepted data.
This story is from the BioSpectrum Asia April 2023 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the BioSpectrum Asia April 2023 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Ushering Fourth Industrial Revolution in Telangana
Taking advantage of the 21st edition of BioAsia 2024 at the Hyderabad International Convention Centre (HICC) in Madhapur, the Government of Telangana, a southern state in India, leveraged the confluence of the global platform to spearhead initiatives aimed at propelling the state into the forefront of the Fourth Industrial Revolution (C4IR).
How Indian Biotech Investments are on a Doubling Spree
A latest report by Ankur Capital provides a closer look at the investments made in biotechnology in the last decade in the country.
"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”
South Korea-based Deep Bio, a pioneering artificial intelligence (AI) healthcare firm focused on cancer pathology, is making waves in the industry.
"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"
Japan-headquartered Daiichi Sankyo, the global healthcare company, launched its subsidiary Daiichi Sankyo Singapore Pte. Ltd. to bridge unmet needs in oncology.
Can Test, Treat, Track Beat Malaria?
Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people.
Engineering CAR T cell sharpshooters
Approved CAR T-cell therapies have shown remarkable results in patients with certain types of blood cancers.
Addressing Challenges in Cell Therapy Manufacturing
Even with significant advancements, there are still anumber of issues with cell therapy manufacturing that need to be resolved as production grows.
"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"
Cell and gene therapy (CGT) expert from Germany, Miltenyi Biotec has recently announced its entry into the Indian market to provide researchers, scientists and clinicians easier access to expertise, research, and manufacturing solutions.
Addressing Accessibility and Affordability of CELL & GENE THERAPIES
Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry.
Korea designs sweat resistant wearable robot sensor
New electromyography (EMG) sensor technology that allows the long-term stable control of wearable robots and is not affected by the wearer's sweat and dead skin has gained attention recently.